消癌平制剂及其绿原酸单体的药动学研究与质量控制
|
摘要
消癌平片和消癌平注射液均为植物通关藤的单味制剂,具有抗癌、消炎、平喘等功效,绿原酸为其中的有效成分之一。研究消癌平制剂的质量控制方法,比较绿原酸单体及制剂在大鼠体内的药物代谢动力学规律,可以为评价消癌平制剂的质量提供方法,并为深入研究消癌平的药效学提供理论依据。
第一部分HPLC法测定消癌平片和消癌平注射液中绿原酸的含量
目的:
建立测定消癌平片和消癌平注射液中绿原酸含量的HPLC法
方法:
色谱柱为Diamonsil(?)(钻石)C18柱(250mm×4.6mm,5μm);流动相为0.2%磷酸-甲醇(65:35);流速为1ml·min~(-1) ;内标为替硝唑;检测波长为327nm;室温;20μl进样。
结果:
在2.22μg·ml~(-1)～96.2μg·ml~(-1)的范围内绿原酸浓度与绿原酸峰面积与内标峰面积的比值呈现良好的线性关系,线性方程为Y=0.0892X+0.0539(n=5), r = 0.9999,方法精密度好,RSD(n=5)为1.72%;方法的回收率为99.9%~103.7%;供试品溶液在分析浓度下,24小时内基本稳定。
结论:
建立了测定消癌平片和消癌平注射液中绿原酸含量的HPLC法,该法灵敏度高,专属性强,适用于消癌平制剂的含量测定。
第二部分消癌平注射液指纹图谱的建立
目的:
建立消癌平注射液HPLC指纹图谱分析方法。
方法:
色谱柱:Diamonsil(?)(钻石)C_(18)柱(250mm×4.6mm,5μm),以A(甲醇):B(磷酸盐缓冲液)为流动相,梯度洗脱(0. 00～10. 00 min,0→5% B;12.00～30.00 min, 5%→20% B;32.00～80.00min,20%→45%B),流速1.0mL·min~(-1) ,检测波长327nm,柱温25℃,进样量20μL。采用《中药色谱指纹图谱相似度评价》(2004年A版)软件,计算10批消癌平注射液HPLC指纹图谱的相似度。
结果:
在消癌平注射液中检测到9个共有指纹峰,各峰分离度良好,以绿原酸峰为参照物峰,各共有峰相对保留时间和相对峰面积的RSD均符合要求。
结论:
所建立的HPLC指纹图谱方法具有较好的精密度、稳定性和重现性,可用于消癌平注射液的质量控制。
第三部分绿原酸血药浓度的HPLC测定法
目的:
建立大鼠血清中绿原酸的HPLC分析方法,为绿原酸的药代动力学研究提供检测技术。
方法:
采用迪马DiamonsilC_(18)色谱柱(250mm×4.6mm,5μm);流动相为0.2%磷酸-甲醇(65:35),流速为1.0ml-min~(-1);替硝唑为内标;检测波长为327 nm。取大鼠血清样品,加入内标,以甲醇去蛋白,0.22μm微孔滤膜过滤,37℃水浴挥干,固体残留物用100μl流动相溶解,20μl进样。
结果:
线性方程为Y=0.4058X+0.9881(r=0.9997),在0.45μg~(-1)12μg范围内,线性关系良好,该分析方法检测限为0.0018μg,最低定量限为0.0062μg,高、中、低三种不同浓度血清样品平均回收率分别为98.55%、104.95%、83.24%,精密度实验RSD值分别为3.83%,2.29%,3.07%,重复性实验RSD值分别为4.64%,1.26%,1.58%。血清中绿原酸在-20℃冷冻避光条件下30天内稳定性较好。
结论:
建立了测定大鼠血清中绿原酸含量的HPLC分析方法,该法灵敏度好,专属性强,能够为绿原酸的药动学研究提供方法支持。
第四部分消癌平制剂及其绿原酸单体的药动学研究
目的:
研究大鼠在灌胃和尾静脉注射绿原酸单体和消癌平制剂后绿原酸在大鼠体内的药动学特征,探讨消癌平制剂中其他成分对绿原酸代谢的影响,阐明绿原酸的药动学变化规律。
方法:
(1)绿原酸组: Wistar大鼠60只,体重180～220g,随机分为6组,每组10只(♂5只,♀5只)。灌胃单次给绿原酸40mg·kg~(-1)、20 mg·kg~(-1)、10 mg·kg~(-1),于给药后10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h尾尖取血0.5ml;尾静脉单次注射绿原酸40mg·kg~(-1)、20 mg·kg~(-1)、10mg·kg~(-1),于给药后5min、10min、20min、30min、45min、60min、90min、120min、180min、240min于尾尖取血约0.5ml,测定绿原酸含量。(2)消癌平组: Wistar大鼠20只,体重180～220g,随机分为2组,每组10只(♂5只,♀5只),其中一组灌胃单次给消癌平溶液20ml·kg~(-1)(相当于CGA 20 mg·kg~(-1)),于给药后10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h尾尖取血0.5 ml。另外一组尾静脉单次给消癌平注射液2.5ml·kg-(1相当于CGA20mg·kg~(-1)),于给药后5min、10min、20min、30min、45min、60min、90min、120min、180min、240min于尾尖取血约0.5 ml,测定绿原酸含量。(3)采用3P97药动学软件处理数据,以最佳房室模型为标准计算每只大鼠的主要药代动力学参数。
结果:
(1)大鼠灌胃绿原酸和消癌平片后,三个剂量组在0-24h的血清中均未能检测出CGA。(2)尾静脉注射高、中、低三种剂量后,绿原酸在大鼠体内的药动学行为均符合二室模型。主要药动学参数为:①iv.40mg·kg~(-1)组:t_(1/2 alpha)=19.781 min,t_(1/2beta)=68.377min,V_c= 0.847L·kg~(-1)·min~(-1),CL_(s)= 0.029L·kg~(-1)·h~(-1);②iv.20 mg·kg~(-1)组: t_(1/2 alpha)=15.221min,t_(1/2 beta)=59.458min,V_c= 0.446L·kg~(-1)·min~(-1),CL_(s)= 0.017L·kg~(-1)·h~(-1);③iv.10 mg·kg~(-1)组: t_(1/2 alpha)=7.878min,t_(1/2beta)=56.783min,V_c= 0.257L·kg~(-1)·min~(-1),CL_(s)= 0.012L·kg~(-1)·min~(-1)。(3)静脉注射消癌平注射液后药动学行为符合二室开放模型,主要药动学参数为: t_(1/2 alpha)=12.559min,t_(1/2beta)=48.283 min,V_c= 0.403L·kg~(-1)·min~(-1),CL_(s)= 0.018L·kg~(-1)·h~(-1)。
结论:
大鼠灌胃给绿原酸和消癌平片后,血清中均未能检测出CGA。大鼠静脉注射绿原酸后,起始阶段血药浓度下降迅速,分布相半衰期t_(1/2 alpha)小于20min,消除相半衰期t_(1/2 beta)约为1h,高剂量组的消除半衰期t_(1/2 beta)明显高于低剂量组,表观分布容积V_c和总清除率CL_(s)与给药剂量呈正相关,随给药剂量的增加,药物在组织与细胞中的浓度增大,机体对药物的清除能力增强。静脉注射消癌平注射液后,制剂中的其他成分对绿原酸的代谢消除有协同作用,表观分布容积与药物总清除率没有明显变化。
Xiaoaiping isolated from the stems of Marsd enia tenacissima, an Asclepiadaceae plant, has been documented to possess functions against inflammation and cancers. The quality control method of Xiaoaiping was investigated.The pharmacokinetics of chlorogenic acid and constituent chlorogenic acid in Xiaoaiping in rats were compared.The quality control method was studied for the evaluation.The results of this study can provide reference for clinic trial and further studies.
Part one The content determination of chlorogenic acid in xiaoaiping tablet and injection by HPLC
Objective:
To establish a HPLC method for the content determination of chlorogenic acid in Xiaoaiping Tablet and injection.
Methods:
The Diamonsil C_(18) column(250mm×4.6mm,5μm) was used.The mobile phase was consisted of 0.2% phosphoric acid with methyl alcohol (65:35). The detective wave length was at 327nm, the velocity of flow was 1.0ml·min~(-1) , the temperature of the column was ambient temperature,and injection volume was 20μl.
Results:
The linear ranges of Chlorogenic acid was 2.22~96.2μg,the linear regression equation was Y=57382X+28096,r = 0.9999, The Precision of chlorogenic acid was good and RSD was 1.72%. The recoveries of high, medium and low concentration were 99.9%~103.7%.When the Signal-to-Noise was 3,LOD(limit of detection) of Chlorogenic acid was 0.00148μg.When the Signal-to-Noise was 10,LOQ (limit of quantitation) of chlorogenic acid was 0.00592μg. The stabiliy of samples was good within 24 hours.
Conclusion:
The method is simple, rapid, accurate . It can be used for the quantitative analysis of xiaoaiping tablet and injection.
Part two Studies on the HPLC fingerprints of Xiaoaiping Injection
Objective:
To establish the chromatographic fingerprint for the quality control of Xiaoaiping injection.
Method:
Analysis on a Diamonsil C18(250mm×4.6mm,5μm)column eluted with mobile phases containing Methanol and Phosphate buffer ingradient mode(0.00～10.00 min, 0→5% B;12.00～30.00 min;5%→20% B;32.00～80.00min,20%→45%B).The flow rate was 1.0 mL·min~(-1),and the detection wavelength was at 327 nm.The temperature of column was 25℃.And the data of 10 batches of Xiaoaiping injection were analysed by“similarity evaluation for chromatographic Fingerprint of Traditional Chinese Medicine”software.
Result:
Nine common peaks were selected in chromatograms,and all the common peeks were separated effectively.Chlorogenic acid peak as the reference peak, the relative retention time and relative peak areas RSD are in line with requirements.
Conclusion:
The precision,stability,and repeatability of this method were satisfying.The method developed can be used to control the quality of Xiaoaiping injection.
Part there Analytical methods of chlorogenic acid in biological samples by HPLC
Objective:
According to the structural characteristics of chlorogenic acid, establish a HPLC analytical methods for serum in rats. so as to provide detecting technology for pharmacokinetic studies .
Methods:
(1)Using Diamonsil C18 chromatographic column (250mm x 4.6 mm, 5μm),mobile phase:0.2%phosphate-methanol(65:35) and velocity of 1.0ml?min~(-1).The internal standard is tinidazole.Uses photodiode array detector. Detected wave length:327nm; (2) Basic methods of biological samples treatment: take 100μl samples and 100ul tinidazole, add 700μl of methanol for extraction and protein deposition, then filtered by 0.22μm microporous membrane, drying by distillation of 37℃water bath, solid residues dissolved with 100μl mobile phase, 20μl for injection.
Results:
Chlorogenic acid work curve of linear range for 0.45μg～112μg(the ratio of CGA and TNZ), Y=0.4058X+0.9881, r=0.9997. the limit of detection was 0.0018μg and the limit of quantification was 0.0062μg. The relative recovery for the analysis of CGA in three different concentrations (high, medium, low) were98.55%、104.95%、83.24%. The precision(RSD) of injection in three different concentrations (high, medium, low) were 3.83%,2.29% and 3.07%,the precision(RSD) of repeatabilit y for the analysis were 4.64%,1.26% and1.58%.The chlorogenic acid in serum has no significant change in 30 days when it was stored in-20℃.
Conclusions:
The measurement of chlorogenic acid in biological samples was achieved by HPLC method. The method was sensitive、specific and simple enough to determine the concentration of chlorogenic acid and to obtain pharmacokinetic parameters.
Part four The Pharmacokinetic study of chlorogenic acid and xiaoaoping in rats
Objective:
To study The pharmacokinetics of chlorogenic acid and constituent chlorogenic acid in Xiaoaiping in rats.
Method:
(1) Chlorogenic acid group: Sixty Wistar rats were divided into 6 groups randomly, each group has 10 rats (♂5,♀5 ) . One group ig. chlorogenic acid 40mg·Kg~(-1) ,20mg·Kg~(-1)and 10mg·Kg~(-1),about 0.5ml blood samples were collected from tail vein before administration and at10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h after administration. another group iv. chlorogenic acid 40mg·Kg~(-1) ,20mg·Kg~(-1)and 10 mg·Kg~(-1) ,about 0.5ml blood samples were collected from tail vein before administration and at 5min、10min、20min、30min、45min、60min、90min、120min、180min、240min after administration. (2) Xiaoaiping group: Twenty Wistar rats were divided into 2 groups randomly, each group has 10 rats(♂5,♀5). One group ig. Xiaoaiping solution 20ml·kg~(-1)(Equivalent to CGA 20 mg·kg~(-1)),about 0.5ml blood samples were collected from tail vein before administration and at10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h after administration. another group iv. Xiaoaiping injection 2.5ml·kg~(-1) ( Equivalent to CGA20mg·kg~(-1) ) about 0.5ml blood samples were collected from tail vein before administration and at 5min、10min、20min、30min、45min、60min、90min、120min、180min、240min after administration. (3) The data was automatic handled with 3P97 pharmacokinetic software, calculating the main pharmacokinetic parameters of each rat with the best compartment model as the standard, using statistical moment method for calculating AUC and MRT values and calculating the absolute bioavailability.
Results:
(1)The three dose groups (high, medium, low) failed to detect the CGA in the 0-24h after rats taked the chlorogenic acid and Xiaoaiping. (2) the mean serum concentration-time curves of chlorogenic acid after iv. with three doses(high, medium, low) were confirmed to open two-compartment model. The main pharmacokinetic parameters were:①Group iv.40mg·kg~(-1):t_(1/2 alpha)=19.781 min,t_(1/2 beta)=68.377min,V_c= 0.847L·kg~(-1)·min~(-1),CL_(s)= 0.029L·kg~(-1)·h~(-1);②Group iv.20 mg·kg~(-1):t_(1/2 alpha)=15.221min, t1/2 beta=59.458min,V_c= 0.446L·kg~(-1)·min~(-1),CL_(s)= 0.017L·kg~(-1)·h~(-1);③Group iv.10 mg·kg~(-1):t_(1/2alpha)=7.878min,t_(1/2beta)=56.783min,V_c=0.257L·kg~(-1)·min~(-1),CL_(s)=0.012L·kg~(-1)·min~(-1). (3) the mean serum concentration-time curves of Xiaoaiping after iv. was confirmed to open two-compartment model. The main pharmacokinetic parameters were: t_(1/2alpha)=12.559min,t_(1/2 beta)=48.283 min,V_c= 0.403L·kg~(-1)·min~(-1),CL_(s)= 0.018L·kg~(-1)·h~(-1).
Conclusions:
The chlorogenic acid can not be detected in the serum after rats taked the chlorogenic acid and Xiaoaiping. The serum concentration of chlorogenic acid declined quickly after iv. in rats, thet_(1/2 alpha) was about 20 min and the t_(1/2 beta) was about 1h, the t_(1/2 beta) of high dosage group was higher than low dosage group significantly. Apparent volume of distribution (V_c) and total clearance (CL (s)) was positively correlated with dose. When dose increases, the concentration in tissue and cell increases, the body's ability to clear drugs enhances. The other components of Xiaoaiping injection have a synergistic effect on the metabolism of chlorogenic acid, apparent volume of distribution and total clearance of drug did not change significantly.
第一部分HPLC法测定消癌平片和消癌平注射液中绿原酸的含量
目的:
建立测定消癌平片和消癌平注射液中绿原酸含量的HPLC法
方法:
色谱柱为Diamonsil(?)(钻石)C18柱(250mm×4.6mm,5μm);流动相为0.2%磷酸-甲醇(65:35);流速为1ml·min~(-1) ;内标为替硝唑;检测波长为327nm;室温;20μl进样。
结果:
在2.22μg·ml~(-1)～96.2μg·ml~(-1)的范围内绿原酸浓度与绿原酸峰面积与内标峰面积的比值呈现良好的线性关系,线性方程为Y=0.0892X+0.0539(n=5), r = 0.9999,方法精密度好,RSD(n=5)为1.72%;方法的回收率为99.9%~103.7%;供试品溶液在分析浓度下,24小时内基本稳定。
结论:
建立了测定消癌平片和消癌平注射液中绿原酸含量的HPLC法,该法灵敏度高,专属性强,适用于消癌平制剂的含量测定。
第二部分消癌平注射液指纹图谱的建立
目的:
建立消癌平注射液HPLC指纹图谱分析方法。
方法:
色谱柱:Diamonsil(?)(钻石)C_(18)柱(250mm×4.6mm,5μm),以A(甲醇):B(磷酸盐缓冲液)为流动相,梯度洗脱(0. 00～10. 00 min,0→5% B;12.00～30.00 min, 5%→20% B;32.00～80.00min,20%→45%B),流速1.0mL·min~(-1) ,检测波长327nm,柱温25℃,进样量20μL。采用《中药色谱指纹图谱相似度评价》(2004年A版)软件,计算10批消癌平注射液HPLC指纹图谱的相似度。
结果:
在消癌平注射液中检测到9个共有指纹峰,各峰分离度良好,以绿原酸峰为参照物峰,各共有峰相对保留时间和相对峰面积的RSD均符合要求。
结论:
所建立的HPLC指纹图谱方法具有较好的精密度、稳定性和重现性,可用于消癌平注射液的质量控制。
第三部分绿原酸血药浓度的HPLC测定法
目的:
建立大鼠血清中绿原酸的HPLC分析方法,为绿原酸的药代动力学研究提供检测技术。
方法:
采用迪马DiamonsilC_(18)色谱柱(250mm×4.6mm,5μm);流动相为0.2%磷酸-甲醇(65:35),流速为1.0ml-min~(-1);替硝唑为内标;检测波长为327 nm。取大鼠血清样品,加入内标,以甲醇去蛋白,0.22μm微孔滤膜过滤,37℃水浴挥干,固体残留物用100μl流动相溶解,20μl进样。
结果:
线性方程为Y=0.4058X+0.9881(r=0.9997),在0.45μg~(-1)12μg范围内,线性关系良好,该分析方法检测限为0.0018μg,最低定量限为0.0062μg,高、中、低三种不同浓度血清样品平均回收率分别为98.55%、104.95%、83.24%,精密度实验RSD值分别为3.83%,2.29%,3.07%,重复性实验RSD值分别为4.64%,1.26%,1.58%。血清中绿原酸在-20℃冷冻避光条件下30天内稳定性较好。
结论:
建立了测定大鼠血清中绿原酸含量的HPLC分析方法,该法灵敏度好,专属性强,能够为绿原酸的药动学研究提供方法支持。
第四部分消癌平制剂及其绿原酸单体的药动学研究
目的:
研究大鼠在灌胃和尾静脉注射绿原酸单体和消癌平制剂后绿原酸在大鼠体内的药动学特征,探讨消癌平制剂中其他成分对绿原酸代谢的影响,阐明绿原酸的药动学变化规律。
方法:
(1)绿原酸组: Wistar大鼠60只,体重180～220g,随机分为6组,每组10只(♂5只,♀5只)。灌胃单次给绿原酸40mg·kg~(-1)、20 mg·kg~(-1)、10 mg·kg~(-1),于给药后10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h尾尖取血0.5ml;尾静脉单次注射绿原酸40mg·kg~(-1)、20 mg·kg~(-1)、10mg·kg~(-1),于给药后5min、10min、20min、30min、45min、60min、90min、120min、180min、240min于尾尖取血约0.5ml,测定绿原酸含量。(2)消癌平组: Wistar大鼠20只,体重180～220g,随机分为2组,每组10只(♂5只,♀5只),其中一组灌胃单次给消癌平溶液20ml·kg~(-1)(相当于CGA 20 mg·kg~(-1)),于给药后10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h尾尖取血0.5 ml。另外一组尾静脉单次给消癌平注射液2.5ml·kg-(1相当于CGA20mg·kg~(-1)),于给药后5min、10min、20min、30min、45min、60min、90min、120min、180min、240min于尾尖取血约0.5 ml,测定绿原酸含量。(3)采用3P97药动学软件处理数据,以最佳房室模型为标准计算每只大鼠的主要药代动力学参数。
结果:
(1)大鼠灌胃绿原酸和消癌平片后,三个剂量组在0-24h的血清中均未能检测出CGA。(2)尾静脉注射高、中、低三种剂量后,绿原酸在大鼠体内的药动学行为均符合二室模型。主要药动学参数为:①iv.40mg·kg~(-1)组:t_(1/2 alpha)=19.781 min,t_(1/2beta)=68.377min,V_c= 0.847L·kg~(-1)·min~(-1),CL_(s)= 0.029L·kg~(-1)·h~(-1);②iv.20 mg·kg~(-1)组: t_(1/2 alpha)=15.221min,t_(1/2 beta)=59.458min,V_c= 0.446L·kg~(-1)·min~(-1),CL_(s)= 0.017L·kg~(-1)·h~(-1);③iv.10 mg·kg~(-1)组: t_(1/2 alpha)=7.878min,t_(1/2beta)=56.783min,V_c= 0.257L·kg~(-1)·min~(-1),CL_(s)= 0.012L·kg~(-1)·min~(-1)。(3)静脉注射消癌平注射液后药动学行为符合二室开放模型,主要药动学参数为: t_(1/2 alpha)=12.559min,t_(1/2beta)=48.283 min,V_c= 0.403L·kg~(-1)·min~(-1),CL_(s)= 0.018L·kg~(-1)·h~(-1)。
结论:
大鼠灌胃给绿原酸和消癌平片后,血清中均未能检测出CGA。大鼠静脉注射绿原酸后,起始阶段血药浓度下降迅速,分布相半衰期t_(1/2 alpha)小于20min,消除相半衰期t_(1/2 beta)约为1h,高剂量组的消除半衰期t_(1/2 beta)明显高于低剂量组,表观分布容积V_c和总清除率CL_(s)与给药剂量呈正相关,随给药剂量的增加,药物在组织与细胞中的浓度增大,机体对药物的清除能力增强。静脉注射消癌平注射液后,制剂中的其他成分对绿原酸的代谢消除有协同作用,表观分布容积与药物总清除率没有明显变化。
Xiaoaiping isolated from the stems of Marsd enia tenacissima, an Asclepiadaceae plant, has been documented to possess functions against inflammation and cancers. The quality control method of Xiaoaiping was investigated.The pharmacokinetics of chlorogenic acid and constituent chlorogenic acid in Xiaoaiping in rats were compared.The quality control method was studied for the evaluation.The results of this study can provide reference for clinic trial and further studies.
Part one The content determination of chlorogenic acid in xiaoaiping tablet and injection by HPLC
Objective:
To establish a HPLC method for the content determination of chlorogenic acid in Xiaoaiping Tablet and injection.
Methods:
The Diamonsil C_(18) column(250mm×4.6mm,5μm) was used.The mobile phase was consisted of 0.2% phosphoric acid with methyl alcohol (65:35). The detective wave length was at 327nm, the velocity of flow was 1.0ml·min~(-1) , the temperature of the column was ambient temperature,and injection volume was 20μl.
Results:
The linear ranges of Chlorogenic acid was 2.22~96.2μg,the linear regression equation was Y=57382X+28096,r = 0.9999, The Precision of chlorogenic acid was good and RSD was 1.72%. The recoveries of high, medium and low concentration were 99.9%~103.7%.When the Signal-to-Noise was 3,LOD(limit of detection) of Chlorogenic acid was 0.00148μg.When the Signal-to-Noise was 10,LOQ (limit of quantitation) of chlorogenic acid was 0.00592μg. The stabiliy of samples was good within 24 hours.
Conclusion:
The method is simple, rapid, accurate . It can be used for the quantitative analysis of xiaoaiping tablet and injection.
Part two Studies on the HPLC fingerprints of Xiaoaiping Injection
Objective:
To establish the chromatographic fingerprint for the quality control of Xiaoaiping injection.
Method:
Analysis on a Diamonsil C18(250mm×4.6mm,5μm)column eluted with mobile phases containing Methanol and Phosphate buffer ingradient mode(0.00～10.00 min, 0→5% B;12.00～30.00 min;5%→20% B;32.00～80.00min,20%→45%B).The flow rate was 1.0 mL·min~(-1),and the detection wavelength was at 327 nm.The temperature of column was 25℃.And the data of 10 batches of Xiaoaiping injection were analysed by“similarity evaluation for chromatographic Fingerprint of Traditional Chinese Medicine”software.
Result:
Nine common peaks were selected in chromatograms,and all the common peeks were separated effectively.Chlorogenic acid peak as the reference peak, the relative retention time and relative peak areas RSD are in line with requirements.
Conclusion:
The precision,stability,and repeatability of this method were satisfying.The method developed can be used to control the quality of Xiaoaiping injection.
Part there Analytical methods of chlorogenic acid in biological samples by HPLC
Objective:
According to the structural characteristics of chlorogenic acid, establish a HPLC analytical methods for serum in rats. so as to provide detecting technology for pharmacokinetic studies .
Methods:
(1)Using Diamonsil C18 chromatographic column (250mm x 4.6 mm, 5μm),mobile phase:0.2%phosphate-methanol(65:35) and velocity of 1.0ml?min~(-1).The internal standard is tinidazole.Uses photodiode array detector. Detected wave length:327nm; (2) Basic methods of biological samples treatment: take 100μl samples and 100ul tinidazole, add 700μl of methanol for extraction and protein deposition, then filtered by 0.22μm microporous membrane, drying by distillation of 37℃water bath, solid residues dissolved with 100μl mobile phase, 20μl for injection.
Results:
Chlorogenic acid work curve of linear range for 0.45μg～112μg(the ratio of CGA and TNZ), Y=0.4058X+0.9881, r=0.9997. the limit of detection was 0.0018μg and the limit of quantification was 0.0062μg. The relative recovery for the analysis of CGA in three different concentrations (high, medium, low) were98.55%、104.95%、83.24%. The precision(RSD) of injection in three different concentrations (high, medium, low) were 3.83%,2.29% and 3.07%,the precision(RSD) of repeatabilit y for the analysis were 4.64%,1.26% and1.58%.The chlorogenic acid in serum has no significant change in 30 days when it was stored in-20℃.
Conclusions:
The measurement of chlorogenic acid in biological samples was achieved by HPLC method. The method was sensitive、specific and simple enough to determine the concentration of chlorogenic acid and to obtain pharmacokinetic parameters.
Part four The Pharmacokinetic study of chlorogenic acid and xiaoaoping in rats
Objective:
To study The pharmacokinetics of chlorogenic acid and constituent chlorogenic acid in Xiaoaiping in rats.
Method:
(1) Chlorogenic acid group: Sixty Wistar rats were divided into 6 groups randomly, each group has 10 rats (♂5,♀5 ) . One group ig. chlorogenic acid 40mg·Kg~(-1) ,20mg·Kg~(-1)and 10mg·Kg~(-1),about 0.5ml blood samples were collected from tail vein before administration and at10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h after administration. another group iv. chlorogenic acid 40mg·Kg~(-1) ,20mg·Kg~(-1)and 10 mg·Kg~(-1) ,about 0.5ml blood samples were collected from tail vein before administration and at 5min、10min、20min、30min、45min、60min、90min、120min、180min、240min after administration. (2) Xiaoaiping group: Twenty Wistar rats were divided into 2 groups randomly, each group has 10 rats(♂5,♀5). One group ig. Xiaoaiping solution 20ml·kg~(-1)(Equivalent to CGA 20 mg·kg~(-1)),about 0.5ml blood samples were collected from tail vein before administration and at10min、30min、1h、1.5h、2h、4h、6h、8h、12h、24h after administration. another group iv. Xiaoaiping injection 2.5ml·kg~(-1) ( Equivalent to CGA20mg·kg~(-1) ) about 0.5ml blood samples were collected from tail vein before administration and at 5min、10min、20min、30min、45min、60min、90min、120min、180min、240min after administration. (3) The data was automatic handled with 3P97 pharmacokinetic software, calculating the main pharmacokinetic parameters of each rat with the best compartment model as the standard, using statistical moment method for calculating AUC and MRT values and calculating the absolute bioavailability.
Results:
(1)The three dose groups (high, medium, low) failed to detect the CGA in the 0-24h after rats taked the chlorogenic acid and Xiaoaiping. (2) the mean serum concentration-time curves of chlorogenic acid after iv. with three doses(high, medium, low) were confirmed to open two-compartment model. The main pharmacokinetic parameters were:①Group iv.40mg·kg~(-1):t_(1/2 alpha)=19.781 min,t_(1/2 beta)=68.377min,V_c= 0.847L·kg~(-1)·min~(-1),CL_(s)= 0.029L·kg~(-1)·h~(-1);②Group iv.20 mg·kg~(-1):t_(1/2 alpha)=15.221min, t1/2 beta=59.458min,V_c= 0.446L·kg~(-1)·min~(-1),CL_(s)= 0.017L·kg~(-1)·h~(-1);③Group iv.10 mg·kg~(-1):t_(1/2alpha)=7.878min,t_(1/2beta)=56.783min,V_c=0.257L·kg~(-1)·min~(-1),CL_(s)=0.012L·kg~(-1)·min~(-1). (3) the mean serum concentration-time curves of Xiaoaiping after iv. was confirmed to open two-compartment model. The main pharmacokinetic parameters were: t_(1/2alpha)=12.559min,t_(1/2 beta)=48.283 min,V_c= 0.403L·kg~(-1)·min~(-1),CL_(s)= 0.018L·kg~(-1)·h~(-1).
Conclusions:
The chlorogenic acid can not be detected in the serum after rats taked the chlorogenic acid and Xiaoaiping. The serum concentration of chlorogenic acid declined quickly after iv. in rats, thet_(1/2 alpha) was about 20 min and the t_(1/2 beta) was about 1h, the t_(1/2 beta) of high dosage group was higher than low dosage group significantly. Apparent volume of distribution (V_c) and total clearance (CL (s)) was positively correlated with dose. When dose increases, the concentration in tissue and cell increases, the body's ability to clear drugs enhances. The other components of Xiaoaiping injection have a synergistic effect on the metabolism of chlorogenic acid, apparent volume of distribution and total clearance of drug did not change significantly.
引文
[1]邢旺兴,程荣珍,陈斌等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
[2]李凯,丛秀峰,赵羲和.消癌平联合榄香烯抑制HeLa细胞增殖和对Bcl-2表达的影响[J].中国肿瘤临床,2008,35(12) :705-708.
[3]李东,欧阳建,李翠萍等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[4]赵陆华,相秉仁,谭喜莹.高效毛细管电泳法测定乌骨藤药材及其制剂中绿原酸的含量[J].中国现代应用药学杂志,2008,25(2):152-154.
[5]刘峰群,曹红,靳守东.等.比色法测定消癌平注射液中总酚酸的含量[J].华西药学杂志,2003,18(3):232-234.
[6]于文静,王焕群.HPLC法测定消癌平口服液中绿原酸的含量[J].中国药品标准2006,7(3):50-52.
[7] Schutz Katrin Muks.Quantitative determination of phenolic compounds in artichoke based dietary supplements and pharmaceuticals by high performance liquid chromatography [J]. Agric Food Chem,2006,54:8812- 8817.
[1]周玉新.中药指纹图谱研究技术[M].北京:化学工业出版社,2002.
[2]刘顺开.河南省新乡市前卫制药厂.消癌平有效成分的提取及剂型制备[P].中国专利: 92102027,1993-10-06.
[3] Gan F,Ye RY. New approach on similarity analysis of chromatographic fingerprint of herbal medicine[J]. Chrom A,2006,1104:100.
[4]国家药品监督管理局.中药注射剂指纹图谱研究的技术要求[S]. (暂行). 2000.
[5]安金兵,许玉琼,贺东奇等.基于拟分布函数的中药包谱指纹图谱的相似性分析[J].北京大学学报:自然科学版,2008,44(5):695.
[6]谢培山.中药现代化的取向与质量控制模式[J].中药新药与临床药理,2002,13(4):201-203.
[7]唐琛霞,阮金兰.指纹图谱技术在中药研究中的应用[J].医药导报,2003,22(7):479 -481.
[8] Begum S,Hassan SI,Siddiqui BS,et al. Triterpenoids from the leaves of Psidium guajava[J]. Phytochemistry,2002,61:399-403.
[1]杨月春,戴其昌.高效液相色谱法测定银黄口服液中的CGA和黄芩苷的含量[J].中国现代应用药学杂志,2004,15(4):54-55.
[2]李俊松,徐德生,冯怡.中药复方的有效组合成分(部位)研究思路[J].上海中医药杂志,2006,40(9):62-64.
[3]高荣,龚涛,符垚等.银黄注射液及口服液中绿原酸和黄芩苷在大鼠体内的药动学比较[J].华西药学杂志,2007,22(3):283-285.
[4]郑筱萸.化学药品制剂人体生物利用度和生物等效性研究指导原则(试行).化学药品临床前药代动力学研究指导原则.第1版.北京:中国医药科技出版社,2002:51.
[5] Naghski J. Isolation of Rutin from Two Varieties of Forsythia intermedia[J]. JAm Chem So,2003(69):572-575.
[6]郑永,陈峰杰,周远大等.绿原酸肠溶胶囊在犬体内的药物动力学及绝对生物利用度[J].华西药学杂志,2003,18(2):103.
[7]陈为烤,居文政,谈恒山.绿原酸的体内过程及药物相互作用[J] .中药药理与临床, 2008,24(3):811-120.
[1]王维信.临床药物代谢动力学[M] .第一版.北京:学苑出版社,1998.
[2]王素军,张志伟,赵艳红等.建立大鼠原位肠-肝灌流模型评价绿原酸的代谢[J].中国临床药理学与治疗学,2006,11(13)40-44.
[3]李钦,张信岳,陈国神.含绿原酸的清热解毒类中药注射剂不良反应及其机理探讨[J].中国现代应用药学杂志,2009,26(7):555-558.
[4]李秋红,冯宇飞,刘佩莉.高剂量双黄连粉针中绿原酸的药动学及其在唾液中的分布[J].中国实验方剂学杂志,2008,14(5):47-49.
[5]居文政,刘芳,吴婷等. UPLC-MS/MS法同时测定血浆中黄芩苷和绿原酸[J].药学学报,2007,42(10):1074-1076.
[6]秦三海,刘华钢.复方银黄微型灌肠剂家兔体内药代动力学研究[J].中国中药杂志,2006,(1):54-56.
[1]国家药品监督管理局药品审评中心.含绿原酸中药注射剂的安全性问题研究总结报告(R) .北京:国家食品药品监督管理局药品审评中心,2006.
[2]钱骅,赵伯涛,张卫明.杜仲叶绿原酸的提取分离[J].中国野生植物资源,2006,20 (4):15-16.
[3]邢旺兴,程荣珍,陈斌等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
[4]石慧,崔炯谟,赵余庆.通光藤抗肿瘤化学成分的研究[J].中国现代中药,2007,9(7):28-30.
[5]马明芳,丁克毅,丁立生等.通关藤的化学成分[J].中草药2009,40(2):183-185.
[6]张慧,裴志东,张修亚等.乌骨藤脂溶性成分抗肿瘤活性及其成分分析[J].中国中药杂志,2010,35(24):25-28.
[7]左小东,崔永安,秦叔逵等.乌骨藤制剂对人肝癌细胞株和表达的影响[J].临床肿瘤学杂志,2010,15(12):62-65.
[8]陈同生,王龙祥,王会营等.荧光共振能量转移技术对肺腺癌活细胞消癌平诱导半胱氨酸天冬氨酸酶3活化过程的实时监测[J].中国组织工程研究与临床康复,2007,11(35):71-72.
[9]李东,欧阳建,李翠萍等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[10]陈军浩,李翠萍.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验[J].中国生化药物杂志,2008,29(1):233-237.
[11]邢旺兴,陈斌,宓鹤鸣等.通光藤中两个新C21甾体苷类成分[J].药学学报,2004,39(4):272-275.
[12]孙珏,沈建华,朱美华等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,34(7):12-14.
[13]王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
[14]王恳,杨万全.局部热疗联合消癌平注射液治疗晚期非小细胞肺癌的临床观察[J].肿瘤基础与临床,2010,23(3):239-241.
[15]曹艳芳.消癌平联合奥宁治疗晚期卵巢癌65例临床观[J].临床医学,2009, 29(1):71-72.
[16] Tsou MF,Hung CF,Lu HF,et al. chloronenic acid ferulicacid on Growth and arylamine N-acetvltransferase activities in Shigella sonne(igroupD)[J].Microbios,2000,101:37-46.
[17] Krakauer T. The polyphenol chloronenic acid inhibits staphylococcal exotoxirr induced inflammatory cvtokines and chcxnokines.I chcxnokines[J].Immmropharm ceeolIrnrnmrocaxicol,2002,24:113-119.
[18]朱卉,朱丹妮,余伯阳.HPLC-CL联用在线检测消癌平注射液清除H2O2及O2·-自由基活性[J].中成药2010 ,32 ( 8 ):1386-1389.
[19]胡宗福,于文利,赵亚平.绿原酸清除活性氧和抗脂质过氧化的研究[J].食品科学,2006,27(2):128-130.
[20]林学政,柳春燕,陈靠山等.不同地域牛蒡叶绿原酸的含量比较及其抑菌试验[J].天然产物研究与开发,2004,16(4):328-330.
[21] Tsou MF,Hung CF,Lu HF,et al. Effects of caffeic acid,chlorogenic acid and ferulic acid on growth and arylamine N-acetyltransferase activity in Shigella sonnei(group D).Micro-bios,2000,101:37-46.
[22]叶星沈,王自力,穆祥等.绿原酸对肠黏膜微血管内皮细胞分泌NO和ET-1的影响[J].解剖与临床,2005,10(2):101-103.
[23] Chiang LC,Chiang W,Chang MY,et al.Antiviral activity of Plantago majorextracts and related compoundsin vitro.An-tiviral Res,2002,55:53-62.
[24] Rodriguez de Sotillo DV,Hadley M.Chlorogenic acid modifiesplasma and liver concentrations of:cholesterol,triacylglycerol,and minerals in (fa/fa) Zucker rats[J]. Nutr Biochem,2002,13:717-726.
[25]胡克杰,孙孝祥,王璟璐.绿原酸体外抗病毒作用研究[J].哈尔滨医科大学学报,2001,35(6):430-432.
[26] Federica Pellati,Stefania Benvenuti. Analysis of phenolic compounds and radical scavenging activity of Echinacea spp.[J].Pharmaceutical and Bio medical Analysis,2004,24(35):289-301.
[27] Phan TT,Sun L,hay BH,et al. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar derived fibroblasts in vitro:therapeutic implication for excessive scarring[J].Trauma,2003,54(12):1212-1224.
[28]罗崇彬.消癌平片抗突变和抗肿瘤作用研究[J].现代医院,2007,7(9):31-33.
[29] Federica Pellati , Stefania Benvenuti. Analysis of phenolic compounds and radical scavenging activity of Echinacea spp.[J].Pharmaceutical and Biomedical Analysis,2004,24(35):289-301.
[30] Ina H,Yamada K,Matsumoto K,et al. Effects of benzyl glucoside and chloronenic acid from Prurrus rnurne on adrenocorti-cotropic hormone(ACTH) and catecholamine levels in plasma of experimental menopausal model rats[J].Biol Pharrn Bull,2004,27:136-137.
[31] Lafay S,Angel GI,Manach C,et al. Chlorogenic Acid Is Absorbed in Its IntactForm in the Stomach of Rats[J]. Br Jnutr,2006,13:192-197.
[32] KonishiY, Kobayashi S. Transepithelial transport of chlorogenic acid,caffeic acidand their colonicmetabolites in intestinal caco-2 cellmonolayers[J].Agric Food Chem,2004,2:2518-2526.
[33] Hollman PCH,Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans[J].Nutr,2001,131:66-71.
[34] Rechner AR,Smith MA,Kuhnle G,et al.Colonicmetabolism of dietary polyphenol:Influence of structure on microbial fermentation products[J]. Free Radic BiolMed,2004,36:212-225.
[35]王素军,张志伟,赵艳红等.建立大鼠原位肠-肝灌流模型评价绿原酸的代谢[J].中国临床药理学与治疗学,2006,11(4)∶1340-1344.
[36] Kang J,Liu Y,Xie MX et al.Interactions of human serum albumin with chlorogenic acid and ferulic acid[J]. Biochim Biophys Acta,2004,1674:205-214.
[37] Bariana DS,Krupey J,Scarpati LM, et al.Chlorogenic acid:further evidence for its antigenic and allergenic activity[J].Nature,1995,207:11-15.
[38] LaurenceL,Layton, et al.Nondiffusible allergenic contaminant isolated from samples of chlorogenic acid causing allergic reactions:pure chlorogenic acid not an allergen[J]. allergy,1996,35:268-275.
[39] AzumaK,IppoushiK,NakayamaM,et al.Absorption ofChlorogenic Acid and Caffeic Acid in Rats after Oral Administration[J] .Agric Food Chem,2007,48:5496-5500.
[40]Moridani MY,ScobieH,Jamshidzadeh A,et al. Caffeic acid,Chlorogenic acidAnd Dihydrocaffeic acid metabolism:glutathione conjugate formation[J].DrugMetab Dispos,2001,29:1432-1439.
[41] Choudhury R,Srai SK, Debnam E, et al. Urinary excretion of hydroxy- cinnamatesand flavonoids after oral and intravenous administration[J]. Free Radic BiolMed,2005,27:278-286.
[42] Booth AN, Emerson OH, Jones FT, et al. Urinary metabolites of caffeic and chlorogenic acids [J]. J Biol Chem, 2001, 229:51-59.
[43]谢岑,钟大放,陈笑艳.鉴定大鼠注射绿原酸后体内的代谢产物[J].药学学报, 2011,46 (1):88-95.
[44] Gonthier MP,Verny MA,Besson C,et al. Chlorogenic Acid Bioavail Ability Largely Depends on ItsMetabolism by the GutMicroflora in Rats[J].Nutr, 2003,133:1853-1859.
[45]胡樱,程明川,杭太俊等.绿原酸和双黄连粉针剂中的成分绿原酸在大鼠体内的药动学比较[J].中国新药与临床杂志,2009,28(4):301-304.
[46]田信,万义,罗飞等.阿霉素与绿原酸在大鼠体内药动学的相互作用[J].华西药学杂志,2009,24(3):256-259.
[2]李凯,丛秀峰,赵羲和.消癌平联合榄香烯抑制HeLa细胞增殖和对Bcl-2表达的影响[J].中国肿瘤临床,2008,35(12) :705-708.
[3]李东,欧阳建,李翠萍等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[4]赵陆华,相秉仁,谭喜莹.高效毛细管电泳法测定乌骨藤药材及其制剂中绿原酸的含量[J].中国现代应用药学杂志,2008,25(2):152-154.
[5]刘峰群,曹红,靳守东.等.比色法测定消癌平注射液中总酚酸的含量[J].华西药学杂志,2003,18(3):232-234.
[6]于文静,王焕群.HPLC法测定消癌平口服液中绿原酸的含量[J].中国药品标准2006,7(3):50-52.
[7] Schutz Katrin Muks.Quantitative determination of phenolic compounds in artichoke based dietary supplements and pharmaceuticals by high performance liquid chromatography [J]. Agric Food Chem,2006,54:8812- 8817.
[1]周玉新.中药指纹图谱研究技术[M].北京:化学工业出版社,2002.
[2]刘顺开.河南省新乡市前卫制药厂.消癌平有效成分的提取及剂型制备[P].中国专利: 92102027,1993-10-06.
[3] Gan F,Ye RY. New approach on similarity analysis of chromatographic fingerprint of herbal medicine[J]. Chrom A,2006,1104:100.
[4]国家药品监督管理局.中药注射剂指纹图谱研究的技术要求[S]. (暂行). 2000.
[5]安金兵,许玉琼,贺东奇等.基于拟分布函数的中药包谱指纹图谱的相似性分析[J].北京大学学报:自然科学版,2008,44(5):695.
[6]谢培山.中药现代化的取向与质量控制模式[J].中药新药与临床药理,2002,13(4):201-203.
[7]唐琛霞,阮金兰.指纹图谱技术在中药研究中的应用[J].医药导报,2003,22(7):479 -481.
[8] Begum S,Hassan SI,Siddiqui BS,et al. Triterpenoids from the leaves of Psidium guajava[J]. Phytochemistry,2002,61:399-403.
[1]杨月春,戴其昌.高效液相色谱法测定银黄口服液中的CGA和黄芩苷的含量[J].中国现代应用药学杂志,2004,15(4):54-55.
[2]李俊松,徐德生,冯怡.中药复方的有效组合成分(部位)研究思路[J].上海中医药杂志,2006,40(9):62-64.
[3]高荣,龚涛,符垚等.银黄注射液及口服液中绿原酸和黄芩苷在大鼠体内的药动学比较[J].华西药学杂志,2007,22(3):283-285.
[4]郑筱萸.化学药品制剂人体生物利用度和生物等效性研究指导原则(试行).化学药品临床前药代动力学研究指导原则.第1版.北京:中国医药科技出版社,2002:51.
[5] Naghski J. Isolation of Rutin from Two Varieties of Forsythia intermedia[J]. JAm Chem So,2003(69):572-575.
[6]郑永,陈峰杰,周远大等.绿原酸肠溶胶囊在犬体内的药物动力学及绝对生物利用度[J].华西药学杂志,2003,18(2):103.
[7]陈为烤,居文政,谈恒山.绿原酸的体内过程及药物相互作用[J] .中药药理与临床, 2008,24(3):811-120.
[1]王维信.临床药物代谢动力学[M] .第一版.北京:学苑出版社,1998.
[2]王素军,张志伟,赵艳红等.建立大鼠原位肠-肝灌流模型评价绿原酸的代谢[J].中国临床药理学与治疗学,2006,11(13)40-44.
[3]李钦,张信岳,陈国神.含绿原酸的清热解毒类中药注射剂不良反应及其机理探讨[J].中国现代应用药学杂志,2009,26(7):555-558.
[4]李秋红,冯宇飞,刘佩莉.高剂量双黄连粉针中绿原酸的药动学及其在唾液中的分布[J].中国实验方剂学杂志,2008,14(5):47-49.
[5]居文政,刘芳,吴婷等. UPLC-MS/MS法同时测定血浆中黄芩苷和绿原酸[J].药学学报,2007,42(10):1074-1076.
[6]秦三海,刘华钢.复方银黄微型灌肠剂家兔体内药代动力学研究[J].中国中药杂志,2006,(1):54-56.
[1]国家药品监督管理局药品审评中心.含绿原酸中药注射剂的安全性问题研究总结报告(R) .北京:国家食品药品监督管理局药品审评中心,2006.
[2]钱骅,赵伯涛,张卫明.杜仲叶绿原酸的提取分离[J].中国野生植物资源,2006,20 (4):15-16.
[3]邢旺兴,程荣珍,陈斌等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
[4]石慧,崔炯谟,赵余庆.通光藤抗肿瘤化学成分的研究[J].中国现代中药,2007,9(7):28-30.
[5]马明芳,丁克毅,丁立生等.通关藤的化学成分[J].中草药2009,40(2):183-185.
[6]张慧,裴志东,张修亚等.乌骨藤脂溶性成分抗肿瘤活性及其成分分析[J].中国中药杂志,2010,35(24):25-28.
[7]左小东,崔永安,秦叔逵等.乌骨藤制剂对人肝癌细胞株和表达的影响[J].临床肿瘤学杂志,2010,15(12):62-65.
[8]陈同生,王龙祥,王会营等.荧光共振能量转移技术对肺腺癌活细胞消癌平诱导半胱氨酸天冬氨酸酶3活化过程的实时监测[J].中国组织工程研究与临床康复,2007,11(35):71-72.
[9]李东,欧阳建,李翠萍等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[10]陈军浩,李翠萍.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验[J].中国生化药物杂志,2008,29(1):233-237.
[11]邢旺兴,陈斌,宓鹤鸣等.通光藤中两个新C21甾体苷类成分[J].药学学报,2004,39(4):272-275.
[12]孙珏,沈建华,朱美华等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,34(7):12-14.
[13]王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
[14]王恳,杨万全.局部热疗联合消癌平注射液治疗晚期非小细胞肺癌的临床观察[J].肿瘤基础与临床,2010,23(3):239-241.
[15]曹艳芳.消癌平联合奥宁治疗晚期卵巢癌65例临床观[J].临床医学,2009, 29(1):71-72.
[16] Tsou MF,Hung CF,Lu HF,et al. chloronenic acid ferulicacid on Growth and arylamine N-acetvltransferase activities in Shigella sonne(igroupD)[J].Microbios,2000,101:37-46.
[17] Krakauer T. The polyphenol chloronenic acid inhibits staphylococcal exotoxirr induced inflammatory cvtokines and chcxnokines.I chcxnokines[J].Immmropharm ceeolIrnrnmrocaxicol,2002,24:113-119.
[18]朱卉,朱丹妮,余伯阳.HPLC-CL联用在线检测消癌平注射液清除H2O2及O2·-自由基活性[J].中成药2010 ,32 ( 8 ):1386-1389.
[19]胡宗福,于文利,赵亚平.绿原酸清除活性氧和抗脂质过氧化的研究[J].食品科学,2006,27(2):128-130.
[20]林学政,柳春燕,陈靠山等.不同地域牛蒡叶绿原酸的含量比较及其抑菌试验[J].天然产物研究与开发,2004,16(4):328-330.
[21] Tsou MF,Hung CF,Lu HF,et al. Effects of caffeic acid,chlorogenic acid and ferulic acid on growth and arylamine N-acetyltransferase activity in Shigella sonnei(group D).Micro-bios,2000,101:37-46.
[22]叶星沈,王自力,穆祥等.绿原酸对肠黏膜微血管内皮细胞分泌NO和ET-1的影响[J].解剖与临床,2005,10(2):101-103.
[23] Chiang LC,Chiang W,Chang MY,et al.Antiviral activity of Plantago majorextracts and related compoundsin vitro.An-tiviral Res,2002,55:53-62.
[24] Rodriguez de Sotillo DV,Hadley M.Chlorogenic acid modifiesplasma and liver concentrations of:cholesterol,triacylglycerol,and minerals in (fa/fa) Zucker rats[J]. Nutr Biochem,2002,13:717-726.
[25]胡克杰,孙孝祥,王璟璐.绿原酸体外抗病毒作用研究[J].哈尔滨医科大学学报,2001,35(6):430-432.
[26] Federica Pellati,Stefania Benvenuti. Analysis of phenolic compounds and radical scavenging activity of Echinacea spp.[J].Pharmaceutical and Bio medical Analysis,2004,24(35):289-301.
[27] Phan TT,Sun L,hay BH,et al. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar derived fibroblasts in vitro:therapeutic implication for excessive scarring[J].Trauma,2003,54(12):1212-1224.
[28]罗崇彬.消癌平片抗突变和抗肿瘤作用研究[J].现代医院,2007,7(9):31-33.
[29] Federica Pellati , Stefania Benvenuti. Analysis of phenolic compounds and radical scavenging activity of Echinacea spp.[J].Pharmaceutical and Biomedical Analysis,2004,24(35):289-301.
[30] Ina H,Yamada K,Matsumoto K,et al. Effects of benzyl glucoside and chloronenic acid from Prurrus rnurne on adrenocorti-cotropic hormone(ACTH) and catecholamine levels in plasma of experimental menopausal model rats[J].Biol Pharrn Bull,2004,27:136-137.
[31] Lafay S,Angel GI,Manach C,et al. Chlorogenic Acid Is Absorbed in Its IntactForm in the Stomach of Rats[J]. Br Jnutr,2006,13:192-197.
[32] KonishiY, Kobayashi S. Transepithelial transport of chlorogenic acid,caffeic acidand their colonicmetabolites in intestinal caco-2 cellmonolayers[J].Agric Food Chem,2004,2:2518-2526.
[33] Hollman PCH,Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans[J].Nutr,2001,131:66-71.
[34] Rechner AR,Smith MA,Kuhnle G,et al.Colonicmetabolism of dietary polyphenol:Influence of structure on microbial fermentation products[J]. Free Radic BiolMed,2004,36:212-225.
[35]王素军,张志伟,赵艳红等.建立大鼠原位肠-肝灌流模型评价绿原酸的代谢[J].中国临床药理学与治疗学,2006,11(4)∶1340-1344.
[36] Kang J,Liu Y,Xie MX et al.Interactions of human serum albumin with chlorogenic acid and ferulic acid[J]. Biochim Biophys Acta,2004,1674:205-214.
[37] Bariana DS,Krupey J,Scarpati LM, et al.Chlorogenic acid:further evidence for its antigenic and allergenic activity[J].Nature,1995,207:11-15.
[38] LaurenceL,Layton, et al.Nondiffusible allergenic contaminant isolated from samples of chlorogenic acid causing allergic reactions:pure chlorogenic acid not an allergen[J]. allergy,1996,35:268-275.
[39] AzumaK,IppoushiK,NakayamaM,et al.Absorption ofChlorogenic Acid and Caffeic Acid in Rats after Oral Administration[J] .Agric Food Chem,2007,48:5496-5500.
[40]Moridani MY,ScobieH,Jamshidzadeh A,et al. Caffeic acid,Chlorogenic acidAnd Dihydrocaffeic acid metabolism:glutathione conjugate formation[J].DrugMetab Dispos,2001,29:1432-1439.
[41] Choudhury R,Srai SK, Debnam E, et al. Urinary excretion of hydroxy- cinnamatesand flavonoids after oral and intravenous administration[J]. Free Radic BiolMed,2005,27:278-286.
[42] Booth AN, Emerson OH, Jones FT, et al. Urinary metabolites of caffeic and chlorogenic acids [J]. J Biol Chem, 2001, 229:51-59.
[43]谢岑,钟大放,陈笑艳.鉴定大鼠注射绿原酸后体内的代谢产物[J].药学学报, 2011,46 (1):88-95.
[44] Gonthier MP,Verny MA,Besson C,et al. Chlorogenic Acid Bioavail Ability Largely Depends on ItsMetabolism by the GutMicroflora in Rats[J].Nutr, 2003,133:1853-1859.
[45]胡樱,程明川,杭太俊等.绿原酸和双黄连粉针剂中的成分绿原酸在大鼠体内的药动学比较[J].中国新药与临床杂志,2009,28(4):301-304.
[46]田信,万义,罗飞等.阿霉素与绿原酸在大鼠体内药动学的相互作用[J].华西药学杂志,2009,24(3):256-259.